32 results
424B5
12y0l9e25y
24 Mar 22
Prospectus supplement for primary offering
4:15pm
PRE 14A
hggpl7qbkzh hrp8vj
1 Sep 21
Preliminary proxy
4:46pm
424B5
qyo5cby79lzibaeq p26
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-10.1
rvl5rtjk0j36 1b7buc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-99.1
vbo769fqjbdznobtu
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
424B3
s8utl4ks
12 Apr 21
Prospectus supplement
1:44pm
S-3
4ise1n7
2 Apr 21
Shelf registration
12:00am